Lourdes Rodríguez Fernández‐Freire

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

E. Daudén, G. Carretero, R. Rivera et al. · Journal of the American Academy of Dermatology · 2020 · 54 citations

Adverse Events, Spanish Registry, Medicine +6

Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

E. del Alcázar, Anna López‐Ferrer, Álvaro Martínez‐Doménech et al. · Dermatologic Therapy · 2021 · 29 citations · Full text

Week 24, Multicentre Study, Clinical Trials +12

Guselkumab: Short‐term effectiveness and safety in real clinical practice

Lourdes Rodríguez Fernández‐Freire, Manuel Galán‐Gutiérrez, José Carlos Armario Hita et al. · Dermatologic Therapy · 2020 · 27 citations

Clinical Effectiveness, Real Clinical Practice, Patient Safety +3

Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Sonsoles Berenguer‐Ruiz, Mario Aparicio‐Domínguez, Pedro Herranz et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 16 citations

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

Ricardo Ruíz‐Villaverde, Lourdes Rodríguez Fernández‐Freire, Pilar Font et al. · Journal of Clinical Medicine · 2022 · 10 citations · Full text